{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:41:35Z","timestamp":1794548495330,"version":"4.9.1"},"reference-count":41,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity and thereby reduce the risk of posttransplant relapse. This phase 1 study investigated the recommended phase 2 dose (RP2D) of venetoclax, a BCL-2 selective inhibitor, when added to FluBu2 in adult patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and MDS\/myeloproliferative neoplasms (MPN) undergoing transplant. Patients received dose-escalated venetoclax (200-400 mg daily starting day \u22128 for 6-7 doses) in combination with fludarabine 30 mg\/m2 per day for 4 doses and busulfan 0.8 mg\/kg twice daily for 8 doses on day \u22125 to day \u22122 (FluBu2). Transplant related\u2013toxicity was evaluated from the first venetoclax dose on day \u22128 to day 28. Twenty-two patients were treated. At study entry, 5 patients with MDS and MDS\/MPN had 5% to 10% marrow blasts, and 18 (82%) of 22 had a persistent detectable mutation. Grade 3 adverse events included mucositis, diarrhea, and liver transaminitis (n = 3 each). Neutrophil\/platelet recovery and acute\/chronic graft-versus-host-disease rates were similar to those of standard FluBu2. No dose-limiting toxicities were observed. The RP2D of venetoclax was 400 mg daily for 7 doses. With a median follow-up of 14.7 months (range, 8.6-24.8 months), median overall survival was not reached, and progression-free survival was 12.2 months (95% confidence interval, 6.0-not estimable). In patients with high-risk AML, MDS, and MDS\/MPN, adding venetoclax to FluBu2 was feasible and safe. To further address relapse risk, assessment of maintenance therapy after venetoclax plus FluBu2 transplant is ongoing. This study was registered at clinicaltrials.gov as #NCT03613532.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005566","type":"journal-article","created":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T23:12:17Z","timestamp":1633821137000},"page":"5536-5545","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Adding venetoclax to fludarabine\/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-8968","authenticated-orcid":false,"given":"H. Moses","family":"Murdock","sequence":"additional","affiliation":[{"name":"Department of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey S.","family":"Cutler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brock","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahasweta","family":"Gooptu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Romee","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Loschi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3327-1283","authenticated-orcid":false,"given":"Jeremy","family":"Ryan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Fell","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Q.","family":"Karp","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4388-0349","authenticated-orcid":false,"given":"Fabienne","family":"Lucas","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8699-2439","authenticated-orcid":false,"given":"Annette S.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Potter","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thelma","family":"Mashaka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Letai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-806X","authenticated-orcid":false,"given":"R. Coleman","family":"Lindsley","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"issue":"2","key":"2021121716302531800_B1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbmt.2011.07.024","article-title":"Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study","volume":"18","author":"Armand","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2021121716302531800_B2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med."},{"issue":"11","key":"2021121716302531800_B3","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","article-title":"Mutation clearance after transplantation for myelodysplastic syndrome","volume":"379","author":"Duncavage","year":"2018","journal-title":"N Engl J Med."},{"issue":"7","key":"2021121716302531800_B4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bbmt.2016.03.029","article-title":"Minimal identifiable disease and the role of conditioning intensity in hematopoietic cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia evolving from myelodysplastic syndrome","volume":"22","author":"Festuccia","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"2021121716302531800_B5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol."},{"issue":"9","key":"2021121716302531800_B6","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv."},{"issue":"35","key":"2021121716302531800_B7","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","article-title":"Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)\/Blood and Marrow Transplant Clinical Trial Network 0502","volume":"33","author":"Devine","year":"2015","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021121716302531800_B8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell."},{"issue":"10","key":"2021121716302531800_B9","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1172\/JCI82908","article-title":"Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia","volume":"126","author":"Bhola","year":"2016","journal-title":"J Clin Invest."},{"issue":"24","key":"2021121716302531800_B10","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood."},{"issue":"7","key":"2021121716302531800_B11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med."},{"issue":"4","key":"2021121716302531800_B12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."},{"issue":"9","key":"2021121716302531800_B13","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood."},{"issue":"12","key":"2021121716302531800_B14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood."},{"issue":"9","key":"2021121716302531800_B15","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021121716302531800_B16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica."},{"issue":"19","key":"2021121716302531800_B17","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021121716302531800_B18","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"2021121716302531800_B19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"2021121716302531800_B20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood."},{"issue":"12","key":"2021121716302531800_B21","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood."},{"issue":"4","key":"2021121716302531800_B22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies","volume":"18","author":"Kluk","year":"2016","journal-title":"J Mol Diagn."},{"issue":"3","key":"2021121716302531800_B23","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat."},{"issue":"6","key":"2021121716302531800_B24","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes\u2014long-term follow-up of the BMT CTN 0901 Clinical Trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"7","key":"2021121716302531800_B25","first-page":"768","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"Clin Oncol."},{"issue":"10","key":"2021121716302531800_B26","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"2021121716302531800_B27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood."},{"issue":"9","key":"2021121716302531800_B28","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3324\/haematol.2015.129650","article-title":"Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation","volume":"100","author":"Kekre","year":"2015","journal-title":"Haematologica."},{"issue":"12","key":"2021121716302531800_B29","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.bbmt.2014.09.007","article-title":"Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"issue":"14","key":"2021121716302531800_B30","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood."},{"issue":"1","key":"2021121716302531800_B31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting","volume":"115","author":"S\u00e1nchez-Abarca","year":"2010","journal-title":"Blood."},{"issue":"21","key":"2021121716302531800_B32","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients [published correction appears in Blood Adv. 2021;5(6):1755-1756]","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv."},{"issue":"6","key":"2021121716302531800_B33","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","article-title":"Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia","volume":"38","author":"Bhatt","year":"2020","journal-title":"Cancer Cell."},{"issue":"30","key":"2021121716302531800_B34","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol."},{"key":"2021121716302531800_B35","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S2152-2650(20)30458-4","article-title":"Mini-hyper-CVD combinations for older adults: results of recent trials and a glimpse into the future","volume":"20","author":"Luskin","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"24","key":"2021121716302531800_B36","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: changing the treatment paradigm [published correction appears in Blood Adv. 2020;4(6):1020]","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv."},{"issue":"25","key":"2021121716302531800_B37","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021121716302531800_B38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood.2019003662","article-title":"Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?","volume":"135","author":"Ciurea","year":"2020","journal-title":"Blood."},{"issue":"1","key":"2021121716302531800_B39","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","article-title":"Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial","volume":"7","author":"Beelen","year":"2020","journal-title":"Lancet Haematol."},{"issue":"3","key":"2021121716302531800_B40","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haematopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol."},{"key":"2021121716302531800_B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2019-124659","article-title":"Post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell transplantation: results of the prospective randomized HOVON-96 trial in recipients of matched related and unrelated donors","volume":"134","author":"De","year":"2019","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/24\/5536\/1853788\/advancesadv2021005566.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/24\/5536\/1853788\/advancesadv2021005566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T12:47:36Z","timestamp":1639745256000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/24\/5536\/477191\/Adding-venetoclax-to-fludarabine-busulfan-RIC"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":41,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,12,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005566","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]}}}